Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 10/20 | 0.70 |
| ▸ | CDK1 | P06493 | 5/20 | 0.56 |
| ▸ | KDR | P35968 | 5/20 | 0.56 |
| ▸ | JAK2 | O60674 | 2/20 | 0.49 |
| ▸ | JAK1 | P23458 | 1/20 | 0.49 |
| ▸ | TYK2 | P29597 | 1/20 | 0.49 |
| ▸ | STAT3 | P40763 | 1/20 | 0.49 |
| ▸ | JAK3 | P52333 | 1/20 | 0.49 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12813273 | 0.83 | AXL (1.00) | AXLCDK1KDRJAK2JAK1 | |
| SCHEMBL12813489 | 0.82 | AXL (0.77) | AXLCDK1KDRJAK2 | |
| SCHEMBL12813376 | 0.82 | AXL (1.00) | AXLCDK1KDR | |
| SCHEMBL12964729 | 0.82 | AXL (1.00) | AXL | |
| SCHEMBL13644150 | 0.82 | AXL (0.73) | AXLCDK1KDRJAK2JAK1 | |
| SCHEMBL21317668 | 0.81 | AXL (0.81) | AXLCDK1KDRJAK2JAK3 | |
| SCHEMBL12964739 | 0.80 | AXL (0.80) | AXLCDK1KDR | |
| SCHEMBL27387131 | 0.80 | AXL (0.70) | AXLCDK1KDRJAK2JAK1 | |
| SCHEMBL12964797 | 0.80 | AXL (0.78) | AXLKDR | |
| SCHEMBL12964795 | 0.78 | AXL (0.75) | AXLJAK2JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230165857-A1 | AXL KINASE INHIBITORS AND USE OF THE SAME | SUMITOMO PHARMA ONCOLOGY, INC. | 2023-06-01 | — | — | US | disclosed |
| US-20210205304-A1 | AXL KINASE INHIBITORS AND USE OF THE SAME | SUMITOMO DAINIPPON PHARMA ONCOLOGY, INC. (US) | 2021-07-08 | — | — | US | disclosed |
| US-11013741-B1 | AXL kinase inhibitors and use of the same | SUMITOMO DAINIPPON PHARMA ONCOLOGY, INC. (US) | 2021-05-25 | — | — | US | disclosed |
| US-10888562-B1 | — | — | 2021-01-12 | — | — | US | disclosed |
| EP-3628665-A1 | SUBSTITUTED N-PHENYLPYRIMIDIN-2-AMINE ANALOGS AS INHIBITORS OF THE AXL KINASE | University of Utah Research Foundation (US) | 2020-04-01 | — | — | EP | disclosed |
| WO-2019195753-A1 | AXL KINASE INHIBITORS AND USE OF THE SAME | TOLERO PHARMACEUTICALS, INC. (US) | 2019-10-10 | — | — | WO | disclosed |
| EP-2693881-B1 | SUBSTITUTED N-PHENYLPYRIMIDIN-2-AMINE ANALOGS AS INHIBITORS OF THE AXL KINASE | UNIV UTAH RES FOUND (US) | 2019-09-04 | — | — | EP | disclosed |
| EP-2693881-B1 | SUBSTITUTED N-PHENYLPYRIMIDIN-2-AMINE ANALOGS AS INHIBITORS OF THE AXL KINASE | UNIV UTAH RES FOUND (US) | 2019-09-04 | — | — | EP | disclosed |
| US-8901120-B2 | Substituted N-phenylpyrimidin-2-amine analogs as inhibitors of the Axl kinase | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2014-12-02 | — | — | US | disclosed |
| US-8901120-B2 | Substituted N-phenylpyrimidin-2-amine analogs as inhibitors of the Axl kinase | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2014-12-02 | — | — | US | disclosed |
| US-8901120-B2 | Substituted N-phenylpyrimidin-2-amine analogs as inhibitors of the Axl kinase | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2014-12-02 | — | — | US | disclosed |
| US-20120283261-A1 | SUBSTITUTED N-PHENYLPYRIMIDIN-2-AMINE ANALOGS AS INHIBITORS OF THE AXL KINASE | SUMITOMO PHARMA ONCOLOGY, INC. | 2012-11-08 | — | — | US | disclosed |
| US-20120283261-A1 | SUBSTITUTED N-PHENYLPYRIMIDIN-2-AMINE ANALOGS AS INHIBITORS OF THE AXL KINASE | SUMITOMO PHARMA ONCOLOGY, INC. | 2012-11-08 | — | — | US | disclosed |
| US-20120283261-A1 | SUBSTITUTED N-PHENYLPYRIMIDIN-2-AMINE ANALOGS AS INHIBITORS OF THE AXL KINASE | SUMITOMO PHARMA ONCOLOGY, INC. | 2012-11-08 | — | — | US | disclosed |
| WO-2012135800-A1 | SUBSTITUTED N-PHENYLPYRIMIDIN-2-AMINE ANALOGS AS INHIBITORS OF THE AXL KINASE | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2012-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120283261-A1 | SUBSTITUTED N-PHENYLPYRIMIDIN-2-AMINE ANALOGS AS INHIBITORS OF THE AXL KINASE | AXL, TYRO3, MERTK | AXL 1/4885CDK1 248/4885KDR 189/4885 |
| US-11013741-B1 | AXL kinase inhibitors and use of the same | AXL, FLT3, TEC | AXL 1/4885CDK1 244/4885KDR 135/4885 |
| US-20210205304-A1 | AXL KINASE INHIBITORS AND USE OF THE SAME | AXL, FLT3, TEC | AXL 1/4885CDK1 198/4885KDR 142/4885 |
| US-20230165857-A1 | AXL KINASE INHIBITORS AND USE OF THE SAME | AXL, FLT3, TEC | AXL 1/4885CDK1 227/4885KDR 144/4885 |
| US-10888562-B1 | — | TP53, TARBP2, FLT3 | AXL 927/4885CDK1 2140/4885KDR 1434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.